Total Payments
$6,917
2024 Payments
$758.91
Companies
15
Transactions
43
Medicare Patients
3,513
Medicare Billing
$355,673
Payment Breakdown by Category
Food & Beverage$4,212 (60.9%)
Consulting$2,000 (28.9%)
Travel$705.30 (10.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,212 | 39 | 60.9% |
| Consulting Fee | $2,000 | 1 | 28.9% |
| Travel and Lodging | $705.30 | 3 | 10.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $2,149 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,646 | 11 | $0 (2020) |
| Genentech USA, Inc. | $932.08 | 8 | $0 (2024) |
| BIOTISSUE HOLDINGS INC. | $345.74 | 4 | $0 (2024) |
| Alcon Laboratories Inc | $296.07 | 3 | $0 (2018) |
| Alcon Vision LLC | $252.82 | 2 | $0 (2024) |
| Allergan Inc. | $248.61 | 3 | $0 (2018) |
| Apellis Pharmaceuticals, Inc. | $232.14 | 2 | $0 (2023) |
| Alimera Sciences, Inc. | $207.18 | 2 | $0 (2021) |
| Mallinckrodt Hospital Products Inc. | $143.92 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $758.91 | 7 | BIOTISSUE HOLDINGS INC. ($345.74) |
| 2023 | $713.25 | 6 | Genentech USA, Inc. ($245.72) |
| 2022 | $283.16 | 3 | EyePoint Pharmaceuticals US, Inc. ($135.00) |
| 2021 | $15.70 | 1 | Alimera Sciences, Inc. ($15.70) |
| 2020 | $2,110 | 2 | Genentech, Inc. ($2,000) |
| 2019 | $1,964 | 13 | Novartis Pharmaceuticals Corporation ($1,536) |
| 2018 | $477.05 | 6 | Alcon Laboratories Inc ($171.08) |
| 2017 | $595.20 | 5 | Genentech USA, Inc. ($247.49) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/11/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $160.37 | General |
| 11/11/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $12.50 | General |
| 10/10/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $160.37 | General |
| 09/26/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $120.14 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/12/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $12.50 | General |
| 06/22/2024 | Alcon Vision LLC | Centurion (Device) | Food and Beverage | In-kind items and services | $143.62 | General |
| Category: Ophthalmology | ||||||
| 05/06/2024 | Genentech, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $149.41 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/04/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $91.47 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/25/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $120.73 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/21/2023 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $143.92 | General |
| Category: IMMUNOLOGY | ||||||
| 05/25/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $112.21 | General |
| Category: Ophthalmology | ||||||
| 03/23/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology and Ophthalmology | ||||||
| 01/24/2023 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $119.93 | General |
| 09/30/2022 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 05/18/2022 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $21.26 | General |
| Category: Ophthalmology | ||||||
| 05/11/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $126.90 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/19/2021 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $15.70 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/12/2020 | Genentech, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Ophthalmology | ||||||
| 02/13/2020 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $109.79 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/03/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $123.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/07/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $112.12 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/11/2019 | Novartis Pharmaceuticals Corporation | BUPARLISIB (Drug) | Food and Beverage | In-kind items and services | $121.75 | General |
| 08/22/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $111.58 | General |
| 07/26/2019 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $285.00 | General |
| 07/26/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Travel and Lodging | In-kind items and services | $210.15 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 891 | 1,857 | $597,524 | $82,969 |
| 2022 | 7 | 837 | 1,817 | $517,082 | $78,861 |
| 2021 | 11 | 1,049 | 1,987 | $549,455 | $132,275 |
| 2020 | 7 | 736 | 1,395 | $356,562 | $61,568 |
Total Patients
3,513
Total Services
7,056
Medicare Billing
$355,673
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 67028 | Injection of drug into eye | Facility | 2023 | 101 | 445 | $271,072 | $36,948 | 13.6% |
| 92134 | Imaging of retina | Facility | 2023 | 350 | 846 | $98,176 | $16,107 | 16.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 90 | 140 | $70,280 | $10,449 | 14.9% |
| 92014 | Established patient complete exam of visual system | Facility | 2023 | 154 | 179 | $87,173 | $10,183 | 11.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 90 | 106 | $37,524 | $5,247 | 14.0% |
| 92004 | New patient complete exam of visual system | Facility | 2023 | 31 | 31 | $18,073 | $2,069 | 11.4% |
| 92250 | Photography of the retina | Facility | 2023 | 61 | 89 | $8,590 | $1,550 | 18.0% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Facility | 2023 | 14 | 21 | $6,636 | $415.68 | 6.3% |
| 67028 | Injection of drug into eye | Facility | 2022 | 100 | 449 | $227,872 | $36,184 | 15.9% |
| 92134 | Imaging of retina | Facility | 2022 | 313 | 836 | $83,246 | $15,741 | 18.9% |
| 92014 | Established patient complete exam of visual system | Facility | 2022 | 152 | 193 | $92,353 | $10,984 | 11.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 80 | 113 | $54,662 | $7,751 | 14.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 99 | 115 | $39,452 | $5,172 | 13.1% |
| 92004 | New patient complete exam of visual system | Facility | 2022 | 21 | 21 | $11,955 | $1,677 | 14.0% |
| 92250 | Photography of the retina | Facility | 2022 | 72 | 90 | $7,542 | $1,352 | 17.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 14 | 46 | $55,338 | $33,733 | 61.0% |
| 67028 | Injection of drug into eye | Facility | 2021 | 97 | 387 | $167,696 | $30,450 | 18.2% |
| 92134 | Diagnostic imaging of retina | Facility | 2021 | 301 | 747 | $71,712 | $14,464 | 20.2% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 11 | 56 | $26,768 | $14,000 | 52.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 83 | 118 | $51,154 | $9,446 | 18.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 116 | 135 | $39,772 | $6,731 | 16.9% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Facility | 2021 | 100 | 111 | $52,614 | $6,600 | 12.5% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 113 | 138 | $21,252 | $4,454 | 21.0% |
| 67028 | Injection of drug into eye | Office | 2021 | 31 | 43 | $16,544 | $3,993 | 24.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 52 | 52 | $14,456 | $3,660 | 25.3% |
About Ala Moshiri, MD PHD
Ala Moshiri, MD PHD is a Ophthalmology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1063619674.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ala Moshiri, MD PHD has received a total of $6,917 in payments from pharmaceutical and medical device companies, with $758.91 received in 2024. These payments were reported across 43 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($4,212).
As a Medicare-enrolled provider, Moshiri has provided services to 3,513 Medicare beneficiaries, totaling 7,056 services with total Medicare billing of $355,673. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Sacramento, CA
- Active Since 06/27/2007
- Last Updated 11/07/2013
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1063619674
Products in Payments
- Lucentis (Biological) $2,315
- BEOVU (Drug) $1,128
- Vabysmo (Drug) $515.27
- Constellation (Device) $280.28
- OZURDEX (Drug) $248.61
- Iluvien (Drug) $191.48
- ACTHAR (Biological) $143.92
- Centurion (Device) $143.62
- YUTIQ (Drug) $135.00
- VABYSMO (Drug) $126.90
- Actemra (Biological) $124.61
- BUPARLISIB (Drug) $121.75
- Tecnis 1-piece IOL (Device) $114.73
- Syfovre (Drug) $112.21
- EYLEA HD (Biological) $91.47
- XIPERE (Drug) $21.26
- ILUVIEN (Drug) $15.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Sacramento
Dr. Carlos Medina Mendez, M.d, M.D
Ophthalmology — Payments: $497,258
Ophthalmology $497,258
Richard Lewis, Md, MD
Ophthalmology — Payments: $455,999
Ophthalmology $455,999
Dr. Lawrence Morse, M.d, M.D
Ophthalmology — Payments: $196,712
Ophthalmology $196,712
Dr. Samuel Lee, M.d, M.D
Ophthalmology — Payments: $186,131
Ophthalmology $186,131
Margaret Chang, M.d, M.D
Ophthalmology — Payments: $178,138
Ophthalmology $178,138
Glenn Yiu, Md, Phd, MD, PHD
Ophthalmology — Payments: $153,812
Ophthalmology $153,812